Multibillion-dollar BridgeBio deal is a boost for patent-centric pharma business models

The deal struck with Helsinn Group is the latest evidence of the new opportunities for IP monetisation provided by hub-and-spokes life sciences companies

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Twitter

20 Oct 2021

@IAM_Alerts Our 5G licensing rates will be ready before mass vehicle roll-out begins, says top @AvanciCompany executive, as the… https://t.co/bRjTXpR4Ho Read more

19 Oct 2021

@IAM_Alerts RT @marconi: Last week, our @Avanci colleague Luke McLeroy spoke at @IAM_Alerts' #AutoIPUSA event in Detroit. On Nov 2, Laurie Fitzgerald… Read more

19 Oct 2021

@IAM_Alerts After a tough 2020 for med-tech deal-making, diagnostic innovation buyouts are driving a resurgence in IP-rich acqu… https://t.co/M44uKPtagj Read more

19 Oct 2021

@IAM_Alerts Ericsson posts strong licensing quarter as it heads into an all-important renewal with Apple https://t.co/xbbxWFsscH https://t.co/KZpjln1pcM Read more

Multibillion-dollar BridgeBio deal is a boost for patent-centric pharma business models

Returning user?

Want to read more?

Adam Houldsworth

TAGS

Twitter